Given the correlation between MFAP5 and ICI insensitivity, targeting MFAP5 could be a promising therapy to improve immunochemotherapy effects in gastric cancer by reshaping the desmoplastic and immunosuppressive microenvironment. Here, MFAP5 is linked to gastric cancer.